Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

Correction to: Drugs 10.1007/s40265-021-01597-9

The members of the REDES Study Group whose names are currently provided as:

Mariana Muñoz Esquerro, Héctor Cabrerizo Carreño, Gemma López Saiz, Celia Pinedo Sierra, Javier González Barcala, Purificación Pérez López Carona, Jacinto Ramos González, Javier Martin Puentes, Gregorio Soto Campos, Francisco Pérez Grimaldi, Juan Luis Garcia Rivero, Celia Gueierrez Villegas, Idoia Salinas Garrido, Cleofé Fernández Aracil, Luis Puente Maestu, Ángela Gómez Sacristán, Miguel Diaz Palacios, Eusebi Chiner Vives, Sandrea Vañes Baños, Rocío Díaz Campos, Ismael García Moguel, Carmen Montero Martínez, María Fernandez Marrube, Tamara Hermida Valverde, Nuria Marina Malanda, Ana Gómez Larrauri, Antonio García Dumpiérrez, Rodolfo Castillo Sainz, Nancy Ortega Rodreguez, Lourdes Almeida Quinatana, Luis Cabanes López, Santiago Quirce Gancedo, Javier Domínguez Ortega, David Romero Ribate, Daniel Laorden Escudero, Antolin López Viña, Andrea Trisán Alonso, Teresa Caruana Careaga, Ana Gómez-Bastero Fernández and Lucía Marín Barrera.

Should be provided as:

Mariana Muñoz, Héctor Cabrerizo, Gemma López, Celia Pinedo, Javier González-Barcala, Purificación Pérez-López-Carona, Jacinto Ramos-González, Javier Martin-Puentes, Gregorio Soto-Campos, Francisco Pérez-Grimaldi, Juan Luis Garcia-Rivero, Celia Gueierrez-Villegas, Idoia Salinas-Garrido, Cleofé Fernández-Aracil, Luis Puente-Maestu, Ángela Gómez-Sacristán, Miguel Diaz-Palacios, Eusebi Chiner-Vives, Sandrea Vañes, Rocío Díaz-Campos, Ismael García-Moguel, Carmen Montero, María Fernandez-Marrube, Tamara Hermida-Valverde, Nuria Marina-Malanda, Ana Gómez-Larrauri, Antonio García-Dumpiérrez, Rodolfo Castillo-Sainz, Nancy Ortega, Lourdes Almeida, Luis Cabanes, Santiago Quirce, Javier Domínguez-Ortega, David Romero, Daniel Laorden, Antolin López-Viña, Andrea Trisán, Teresa Caruana-Careaga, Ana Gómez-Bastero and Lucía Marín-Barrera.

Section 1. Introduction, third paragraph, fifth sentence, which currently reads:

However, several single-centre real-life studies have shown evidence of the effectiveness of mepolizumab [15–18]

Should read:

Also, several single-centre real-life studies have shown evidence of the effectiveness of mepolizumab [15–18]

Section 1. Introduction, fourth paragraph, second sentence, which reads:

On the other hand, it has also been postulated that the lower the peripheral blood eosinophil value achieved by biological treatment, the better the clinical outcome.

Should be deleted.

Section 2.2 Outcome, fifth sentence, which currently reads:

Two stratifications were carried out to baseline eosinophil levels: by ranges (< 150 eosinophils/µL, ≥ 150 and < 300/µL and ≥ 300 and < 500 eosinophils/µL at treatment initiation) and by lower thresholds: ≥ 150 eosinophils/µL, ≥ 300 eosinophils/µL, ≥ 500 eosinophils/µL and ≥ 700 eosinophils/µL at treatment initiation).

Should read:

Two stratifications were carried out to baseline eosinophil levels: by ranges (< 150 eosinophils/μL, ≥ 150 eosinophils/μL and < 300 eosinophils/μL, ≥ 300 eosinophils/μL and < 500 eosinophils/μL and ≥ 700 eosinophils/μL at treatment initiation).

Section 2.3 Study Measurements, second paragraph, second sentence, which currently reads:

For this, patients were grouped according to their baseline blood eosinophil counts (≥ 150 cells/μL, ≥ 300 cells/μL, ≥ 500 cells/μL and ≥ 750 cells/μL), and baseline blood eosinophil ranges (< 150 cells/μL, 150–299 cells/μL, 300–499 cells/μL, 500–699 cells/μL and ≥ 700 cells/μL).

Should read:

For this, patients were grouped according to their baseline blood eosinophil counts (≥ 150 cells/μL, ≥ 300 cells/μL, ≥ 500 cells/μL and ≥ 700 cells/μL), and baseline blood eosinophil ranges (< 150 cells/μL, 150–299 cells/μL, 300–499 cells/μL, 500–699 cells/μL and ≥ 700 cells/μL).

Section 2.4 Sample Population Size Calculation, fourth sentence, which currently reads:

The power analysis considered a sample size of 350, after assuming an assumed 10% of missing data, meaning that we would need to include 320 patients.

Should read:

The power analysis considered a sample size of 350, after assuming a 10% of missing data, meaning that we would need to include 320 patients.

Section 3.2 Previous Treatment, second paragraph, second sentence, which currently reads:

Two hundred and ninety-four (92.5%) of the patients continued to receive mepolizumab; three patients (0.9%) discontinued mepolizumab treatment 6 months, the main reason being inadequate control and adverse events (Table 2).

Should read:

Two hundred and ninety-four (92.5%) of the patients continued to receive mepolizumab; three patients (0.9%) discontinued mepolizumab treatment at 6 months, the main reason being inadequate control and adverse events (Table 2).

References

Reference 1. The authors should be listed as

Domingo Ribas C, Sogo Sagardia A, Prina E, Sicras Mainar A, Sicras Navarro A, Engroba Teijeiro C.

Reference 3. The first author should be listed as

Plaza Moral V.

Reference 12. Citation details should read

Allergy. 2019;74(9):1716–1726. 10.1111/all.13850

Reference 13. The authors should be listed as

Enríquez-Rodríguez AI, Hermida Valverde T, Romero Álvarez P, López-González FJ, Gullón Blanco JA, Expósito Villegas AR, et al.

Reference 38. The authors should be listed as

Álvarez Gutiérrez FJ, Blanco Aparicio M, Plaza V, Cisneros C, García Rivero JL, Padilla A, et al.

The original article has been update.